Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Ki‐Hun Kim, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Kyu‐Bo Sung, Gi‐Young Ko, Byungchul Cho, Kyoung Won Kim, Sung‐Gyu Lee – 5 December 2011 – Because revascularization of the inferior right hepatic vein (IRHV) is a major component of right liver graft (RLG) reconstruction, we assessed the surgical techniques and clinical outcomes of IRHV reconstruction so that we could formulate practical guidelines for standardized procedures.

Ashley N. Bedel, Trina S. Hemmelgarn, Rohit Kohli – 5 December 2011 – Cytomegalovirus (CMV) is the most common viral infection after solid organ transplantation (SOT). Safe and effective prophylactic regimens that decrease its incidence after SOT are essential for long‐term graft survival. Although valganciclovir is not Food and Drug Administration–approved for CMV prophylaxis in liver transplant recipients, postmarketing studies have shown valganciclovir to be as effective as ganciclovir in high‐risk adult patients undergoing SOT.

Mazen Albeldawi, Ashish Aggarwal, Surabhi Madhwal, Jacek Cywinski, Rocio Lopez, Bijan Eghtesad, Nizar N. Zein – 5 December 2011 – As survival after orthotopic liver transplantation (OLT) improves, cardiovascular (CV) disease has emerged as the leading cause of non–graft‐related deaths. The aims of our study were to determine the cumulative risk of CV events after OLT and to analyze predictive risk factors for those experiencing a CV event after OLT. We identified all adult patients who underwent OLT at our institution for end‐stage liver disease between October 1996 and July 2008.

David Da Ines, Wassim Essamet, Pierre F. Montoriol – 2 December 2011

Silvia Ruiz‐Gaspà, Angels Martinez‐Ferrer, Nuria Guañabens, Marta Dubreuil, Pilar Peris, Anna Enjuanes, Maria Jesús Martinez de Osaba, Luisa Alvarez, Ana Monegal, Andrés Combalia, Albert Parés – 2 December 2011 – Low bone formation is considered to be the main feature in osteoporosis associated with cholestatic and end‐stage liver diseases, although the consequences of retained substances in chronic cholestasis on bone cells have scarcely been studied.

Katia Bourd‐Boittin, Dominique Bonnier, Anthony Leyme, Bernard Mari, Pierre Tuffery, Michel Samson, Frédéric Ezan, Georges Baffet, Nathalie Theret – 2 December 2011

Robert A. Fridell, Chunfu Wang, Jin‐Hua Sun, Donald R. O'Boyle, Peter Nower, Lourdes Valera, Dike Qiu, Susan Roberts, Xin Huang, Bernadette Kienzle, Marc Bifano, Richard E. Nettles, Min Gao – 2 December 2011 – The NS5A replication complex inhibitor, BMS‐790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single‐ascending dose study and a 14‐day multiple‐ascending dose (MAD) monotherapy study.

Yun Ku Cho, Jin Wook Chung, Yoonjung Kim, Hyun Je Cho, Soo Hyun Yang – 2 December 2011 – High‐grade dysplastic nodules (HGDNs) are known to be premalignant lesions of hepatocellular carcinoma (HCC). We devised a model to estimate the long‐term survival benefit of treating HGDNs by radiofrequency ablation (RFA) (Group I), as compared with regular follow‐up and timely treatment by resection (Group II). A hypothetical 60‐year‐old compensated patient with cirrhosis was assumed.

Raquel Urtasun, Maria U. Latasa, Maria I. Demartis, Stella Balzani, Saioa Goñi, Oihane Garcia‐Irigoyen, Maria Elizalde, Maria Azcona, Rosa M. Pascale, Francesco Feo, Paulette Bioulac‐Sage, Charles Balabaud, Jordi Muntané, Jesus Prieto, Carmen Berasain, Matias A. Avila – 2 December 2011 – The identification of molecular mechanisms involved in the maintenance of the transformed phenotype of hepatocellular carcinoma (HCC) cells is essential for the elucidation of therapeutic strategies.

Silvia Sookoian, Carlos J. Pirola – 2 December 2011